Home › Hidradenitis Suppurativa › NCT05403710

Targeting Nociceptors in Hidradenitis Suppurativa

Who can join

Ages 18 to 75 · All sexes

Inclusion:

* Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS)
* HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas

Exclusion:

* Age \< 18 years or \> 75 years
* pregnant or breastfeeding
* neuromuscular disorder (ex. ALS, myasthenia gravis, Lambert-Eaton syndrome, myopathy)
* medical co-morbidity that is a relative contraindication to skin biopsy procedure (ex. end stage congestive heart failure or coagulopathy)
* active bacterial, fungal, or viral infection in the treatment area
* known hypersensitivity to botulinum toxin A preparations or any of their components (human albumin, saline, lactose, sodium succinate)
* prisoners
* adults unable to consent for themselves.

About the study

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.

What is being tested

• Botulinum toxin (drug)

Sponsor: University of Massachusetts, Worcester · Participants: 20 · Started: Jun 7, 2022

Contact the study team

• Sarah K Whitley, MD PhD · Phone: (508)856-4086
• Deborah White, Deborah Peduzzi · Phone: (508)856-2664

Official record on ClinicalTrials.gov — NCT05403710

Locations in the U.S.

Conditions

• Hidradenitis Suppurativa

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.